About Hanimune Therapeutics
Hanimune Therapeutics is a private company based in Philadelphia, Pennsylvania. It has reported $4,743,648 raised in four offerings on Form D since February 2019. Its chief executive is Meenal Lele.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Jan 24, 2023 | Feb 7, 2023 | $3,304,288of $5.0M target | 33 | $100K | EquityRule 506(b) | Form D ↗ |
| Feb 25, 2021 | Mar 10, 2021 | $759,360fully sold | 16 | $47,460 | Equity, Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Sep 16, 2019 | Nov 25, 2019 | $0target not set | 1 | $0 | Equity, Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Jan 25, 2019 | Feb 26, 2019amended Nov 22, 2019 | $680,000of $1.0M target | 14 | $48,571 | Simple Agreement for Future EquityRule 506(b) | Form D/A ↗2 earlier filings |
| Total, four offerings | $4,743,648 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Hanimune Therapeutics's Form D filed Feb 7, 2023.
ML
Meenal Lele
Chief Executive Officer and director
HM
Hany Michail
Director